What's new

Covaxin effectively neutralises Alpha, Delta variants of Covid: US top health institute

INDIAPOSITIVE

ELITE MEMBER
Joined
Sep 20, 2014
Messages
9,318
Reaction score
-28
Country
India
Location
India
The National Institute of Health (NIH) in the United States has found that Bharat Biotech's Covaxin vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of Covid-19.

The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the "highly efficacious" Covaxin Covid-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

"Results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively," NIH said in a statement.

The adjuvant used in Covaxin, Alhydroxiquim-II, was discovered and tested in the laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support exclusively from the NIAID Adjuvant Development Program, NIH said. The adjuvant comprises a small molecule attached in a unique way to Alhydrogel, a substance frequently called alum that is the most commonly used adjuvant in vaccines for people.

"Ending a global pandemic requires a global response," said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. "I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious Covid vaccine available to people in India."

Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Published results from a Phase 2 trial of the vaccine indicate that it is safe and well-tolerated.

Unpublished interim results from the Phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against


 
.
Covaxin: Delhi highest in percentage of doses administered, five Northeast states miss out


As of June 30, the number of Covaxin doses administered across the states stood at 3,61,35,097, according to the Centre’s CoWin dashboard
 
.
Those who gave haha reacts are ones who rename chinese vaccine as their own as they don’t have capability to make their own vaccines.

Proud recipient of Covaxin, took first dose 2 days back.


India’s biotech companies like Zydus Cadilla, Biological-E and Gennova India have developed their own Vaccines to be mass produced in India and are under trials, Sputnik-V, Novavax, Astrazeneca are being license manufactured in India, now moderna vaccines are allowed to be imported. J&J’s single dose vaccine is also going to be produced in India. Bharat Biotech who makes the Covaxin has also made it’s naval wuhan virus vaccine and is under trials. Hyderabad based Biological-E is also making a new mRNA wuhan virus vaccine. So PM’s vaccination target can be achieved on time. Don’t know how many more are developing their own Wuhan Virus vaccines, hope that we become surplus vaccine producer by end of this year. 10 million doses a day is the only solution.
 
Last edited:
.

Pakistan Affairs Latest Posts

Back
Top Bottom